Residency · Residency · Dermatology

Rosacea: Subtypes, Triggers, and Therapeutics

Overview

Rosacea is a common chronic inflammatory dermatosis primarily affecting the central face, characterized by persistent facial erythema, telangiectasias, papules, pustules, and in severe cases, phymatous changes. It affects approximately 5 to 10 percent of the population, predominantly fair-skinned individuals, and has a significant impact on quality of life.

Epidemiology

Rosacea has a prevalence of 5 to 10 percent, though it is likely underdiagnosed. Peak onset occurs between ages 30 and 50. The condition is more common in individuals of Celtic and Northern European descent (Fitzpatrick skin types I and II), though it is increasingly recognized in skin of color, where erythema may be subtle and papulopustular changes predominate. There is an overall female predominance, although phymatous changes are more common in men.

Pathogenesis

Neurovascular Dysregulation

Abnormal vasomotor control leads to persistent vasodilation and flushing. Transient receptor potential vanilloid (TRPV) channels on sensory neurons are activated by triggers such as heat, spice, and alcohol. Increased VEGF expression contributes to angiogenesis and telangiectasia formation, while neurogenic inflammation occurs via substance P and CGRP release.

Innate Immune Dysfunction

The key pathway involves cathelicidin/LL-37 dysregulation. Keratinocytes overexpress kallikrein 5 (KLK5), a serine protease that cleaves cathelicidin into LL-37 fragments. These abnormal LL-37 peptides promote inflammation, angiogenesis, and leukocyte recruitment, making this pathway central to the inflammatory component of rosacea. TLR2 overexpression on keratinocytes enhances innate immune activation, and mast cell activation contributes to both flushing and inflammation.

Demodex Mites

Demodex folliculorum and D. brevis are commensal mites residing in pilosebaceous units. Rosacea patients have significantly higher Demodex density, exceeding 5 mites per cm2 on standardized skin surface biopsy. Demodex may contribute to inflammation through mechanical follicular obstruction, by carrying Bacillus oleronius bacteria that activate innate immunity, and by releasing antigens upon mite death that trigger an inflammatory response. The efficacy of anti-Demodex therapies such as ivermectin and metronidazole in rosacea supports a pathogenic role for these mites.

UV Radiation

Chronic UV exposure damages dermal connective tissue and vasculature, activates matrix metalloproteinases and VEGF, and contributes to telangiectasia formation and elastotic degeneration. Photoprotection is therefore a cornerstone of management.

Classification (Updated Phenotypic Approach)

Diagnostic Features (one is sufficient for diagnosis)

Either fixed centrofacial erythema that may periodically intensify, or phymatous changes, is sufficient to make the diagnosis.

Major Features (two or more support diagnosis)

Major features that support the diagnosis include flushing or transient erythema, papules and pustules, telangiectasias, and ocular manifestations with lid or periocular involvement.

Traditional Subtypes (still clinically useful)

Erythematotelangiectatic rosacea (ETR) presents with persistent centrofacial erythema lasting more than three months, flushing episodes triggered by heat, spice, alcohol, emotion, or exercise, telangiectasias on the cheeks and nose, skin sensitivity with stinging and burning, and minimal papulopustular component.

Papulopustular rosacea features central facial papules and pustules superimposed on erythema. The key distinguishing feature from acne is the absence of comedones. It has a perioral, perinasal, and cheek distribution and may coexist with ETR features.

Phymatous rosacea involves skin thickening from fibrosis, sebaceous gland hyperplasia, and edema. Rhinophyma, the most common form, presents as a bulbous, erythematous, thickened nose. Other forms include gnatophyma (chin), metophyma (forehead), otophyma (ears), and blepharophyma (eyelids). This subtype is more common in men and, importantly, does not correlate with alcohol use, despite the common misconception.

Ocular rosacea may occur with or without skin findings and is often underdiagnosed. It presents with blepharitis, meibomian gland dysfunction, conjunctival injection, foreign body sensation, burning, tearing, and photophobia. Corneal involvement, including keratitis and corneal neovascularization, can threaten vision. Lid hygiene and systemic therapy are the mainstays of treatment.

Granulomatous Rosacea

Granulomatous rosacea presents as firm, yellow-brown or erythematous papules on the face with non-caseating granulomas on histology. The differential includes sarcoidosis, perioral dermatitis, and lupus miliaris disseminatus faciei.

Differential Diagnosis

Acne vulgaris is distinguished by the presence of comedones, younger age of onset, and T-zone distribution. Seborrheic dermatitis shows greasy scale in the nasolabial folds and eyebrows. Lupus erythematosus features a malar rash that spares the nasolabial folds with systemic features. Contact dermatitis follows allergen exposure distributions and is confirmed by patch testing. Perioral dermatitis produces papules and pustules around the mouth and is often associated with topical corticosteroid use. Carcinoid syndrome causes episodic flushing with elevated 5-HIAA. Polycythemia vera produces a plethoric face with elevated hemoglobin. Dermatomyositis presents with a heliotrope rash that is periorbital, accompanied by muscle weakness.

Histopathology

In ETR, findings include dermal edema, vascular ectasia, perivascular lymphocytic infiltrate, and solar elastosis. Papulopustular rosacea shows perifollicular neutrophilic infiltrate and Demodex mites within follicular infundibula. Phymatous rosacea demonstrates sebaceous gland hyperplasia, dermal fibrosis, and chronic inflammation. Granulomatous rosacea reveals non-caseating epithelioid granulomas.

Triggers and Avoidance

The most common trigger is sun and UV exposure. Additional triggers include heat and hot beverages, spicy food (capsaicin activates TRPV1), alcohol (especially red wine), emotional stress, wind and cold weather, hot baths and exercise, and topical irritants such as harsh skincare products and fragrances. Importantly, topical corticosteroids can cause steroid rosacea, and vasodilating medications may also provoke flares.

Management

General Measures

General measures include gentle skincare with fragrance-free, non-irritating cleansers and moisturizers, daily broad-spectrum sunscreen (SPF 30 or higher) with mineral formulations (zinc or titanium) preferred for sensitive skin, trigger identification and avoidance using a diary, and green-tinted cosmetic camouflage for erythema.

Erythema/Flushing

Brimonidine 0.33% gel is an alpha-2 adrenergic agonist and topical vasoconstrictor that reduces erythema within 30 minutes with a duration of 12 hours, though rebound erythema is possible. Oxymetazoline 1% cream is an alpha-1A adrenergic agonist with less rebound than brimonidine. Vascular laser and IPL are the gold standard for telangiectasias: pulsed dye laser (595 nm) targets hemoglobin and is excellent for telangiectasias, KTP laser (532 nm) treats superficial vessels, and IPL with its broader spectrum is effective for diffuse erythema. Multiple sessions are typically needed with maintenance treatments.

Papulopustular Rosacea

First-line topical therapies for mild-to-moderate disease include ivermectin 1% cream, which has both anti-Demodex and anti-inflammatory properties, is applied once daily, and has demonstrated superiority to metronidazole in head-to-head trials. Metronidazole 0.75 to 1% cream or gel is applied twice daily and works through an anti-inflammatory mechanism. Azelaic acid 15% gel is anti-inflammatory and antimicrobial and also helps with post-inflammatory erythema. Sodium sulfacetamide/sulfur preparations and minocycline foam 1.5% are additional options.

For moderate-to-severe disease, systemic therapies include low-dose doxycycline (40 mg modified-release daily), which functions at a sub-antimicrobial anti-inflammatory dose by inhibiting MMP activity and neutrophil chemotaxis, with fewer side effects than full-dose antibiotics. Standard doxycycline (50 to 100 mg daily) or minocycline (50 to 100 mg daily) is used for more severe cases. Low-dose isotretinoin (0.25 to 0.5 mg/kg/day) treats refractory papulopustular rosacea by reducing sebum and inflammation. Oral ivermectin (200 mcg/kg) is reserved for severe Demodex-associated disease.

Phymatous Rosacea

In early, inflammatory phymatous rosacea, oral isotretinoin can reduce tissue hypertrophy. Established rhinophyma requires surgical intervention, including CO2 laser ablation, electrosurgery or radiofrequency, surgical decortication or dermabrasion, or excision and grafting for severe cases. Medical therapy alone is insufficient for established phymatous changes.

Ocular Rosacea

Treatment includes daily warm compresses and lid hygiene, artificial tears, oral doxycycline (40 to 100 mg daily) as the mainstay, topical cyclosporine 0.05% ophthalmic emulsion for refractory cases, and ophthalmology referral for corneal involvement.

<image>Clinical photograph panel showing the four rosacea subtypes: (A) erythematotelangiectatic with central facial erythema and telangiectasias on the cheeks, (B) papulopustular with inflammatory papules and pustules on erythematous background without comedones, (C) phymatous showing rhinophyma with bulbous nasal enlargement, (D) ocular rosacea with blepharitis and conjunctival injection. Show on fair and medium skin tones.</image>

<image>Pathogenesis diagram of rosacea showing the interplay of neurovascular dysregulation (TRPV channel activation, neuropeptide release), innate immune dysfunction (KLK5/cathelicidin/LL-37 pathway, TLR2 activation), Demodex mite infestation with Bacillus oleronius, UV damage, and vascular changes. Map therapeutic targets including ivermectin (anti-Demodex), doxycycline (anti-MMP/anti-inflammatory), brimonidine (vasoconstriction), and laser (vascular ablation).</image>

<image>Treatment algorithm for rosacea organized by phenotype: erythema/flushing pathway (brimonidine, oxymetazoline, laser/IPL), papulopustular pathway (topical ivermectin/metronidazole/azelaic acid, then systemic doxycycline, then isotretinoin), phymatous pathway (isotretinoin early, surgical for established), and ocular pathway (lid hygiene, doxycycline, cyclosporine ophthalmic). Show as branching flowchart with severity escalation.</image>

Key Clinical Pearls

The absence of comedones is the key clinical feature distinguishing rosacea from acne vulgaris; if comedones are present, consider acne or combined acne-rosacea. Topical corticosteroids worsen rosacea and can cause "steroid rosacea" (perioral dermatitis with papules, pustules, and telangiectasia), so they should never be used to treat rosacea. Ivermectin 1% cream has replaced metronidazole as the preferred topical for papulopustular rosacea based on superior head-to-head trial data. Low-dose doxycycline (40 mg modified-release) is anti-inflammatory without antibiotic effects, avoiding concerns about antimicrobial resistance. Rhinophyma is not caused by alcohol use, and perpetuating this myth is a harmful stigma; it is a fibrotic and sebaceous hypertrophic process requiring surgical correction. All rosacea patients should be asked about eye symptoms, as ocular rosacea is underdiagnosed and can lead to corneal damage if untreated.

References

• Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148-155.
• Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749-758.
• Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015;72(5):761-770.
• Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea. Br J Dermatol. 2015;172(4):1103-1110.

Read this lecture as Markdown